Citicoline is NOT Recommended for Acute Ischemic Stroke
Citicoline should not be used as an adjunct to standard acute stroke therapy in adult patients with acute ischemic stroke. The highest quality evidence—the 2013 AHA/ASA Guidelines—explicitly states that "no agent with putative neuroprotective effects can be recommended for the treatment of patients with acute ischemic stroke" 1. This recommendation is based on the failure of the large International Citicoline Trial on Acute Stroke (ICTUS), which enrolled 2,298 patients with moderate to severe ischemic strokes and was stopped prematurely in 2011 due to futility, showing no difference in 90-day outcomes (OR 1.03; 95% CI 0.86-1.25; P=0.364) 1.
Why Citicoline Failed Despite Early Promise
The evidence trajectory for citicoline demonstrates a classic pattern of initial optimism followed by definitive negative results:
- Early trials showed potential benefit in post-hoc analyses, with one meta-analysis suggesting 25.2% recovery in citicoline-treated patients versus 20.2% in placebo (P=0.0034) 2
- However, none of the individual clinical trials that contributed to these meta-analyses demonstrated benefit 2
- The definitive ICTUS trial (2011) definitively showed no benefit 1
- Most recent systematic reviews (2020 Cochrane review of 10 RCTs with 4,281 participants) confirm there is "little to no difference" in all-cause mortality (RR 0.94,95% CI 0.83-1.07), disability/dependence (RR 1.11,95% CI 0.97-1.26), or functional recovery 3
The Evidence Quality Problem
The available citicoline research suffers from critical methodological flaws:
- All 10 trials in the Cochrane review were assessed as having high risk of bias 3
- Six trials were sponsored by drug companies 3
- The overall quality of evidence is rated as low due to design and execution limitations 3
- Adverse events were poorly reported, suggesting potential underestimation of harms 3
What You Should Do Instead
For acute ischemic stroke within 48 hours, the evidence-based approach is:
- Aspirin 160-325 mg orally within 24-48 hours of stroke onset (Grade 1A recommendation) 4
- NOT within 24 hours of IV rtPA if thrombolysis was given 1
- Standard supportive care including blood pressure management, glucose control, and DVT prophylaxis
Common Pitfall to Avoid
Do not be misled by:
- Older meta-analyses suggesting benefit (these were based on post-hoc analyses of failed trials)
- Small observational studies from single countries showing improvement 5
- Mechanistic studies showing biological effects (like increased endothelial progenitor cells 6) that don't translate to clinical benefit
The 2026 AHA/ASA Guidelines 7 and most recent expert guidance 8 make no mention of citicoline, effectively confirming its lack of role in modern stroke care.
Bottom line: Citicoline has no established dosing regimen for acute ischemic stroke because it should not be used at all. Focus on proven therapies: thrombolysis (if eligible), endovascular thrombectomy (for large vessel occlusion), and early aspirin.